



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features**

**Citation for published version:**

Firdaus Francis, F, Ballerini, L & Wardlaw, J 2019, 'Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis', *International Journal of Stroke*. <https://doi.org/10.1177/1747493019830321>

**Digital Object Identifier (DOI):**

[10.1177/1747493019830321](https://doi.org/10.1177/1747493019830321)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

International Journal of Stroke

**Publisher Rights Statement:**

This is the authors' peer-reviewed manuscript as accepted for publication.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



**Title:** Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis

**Short Title:** Perivascular spaces associations

**Authors:** Farah Francis<sup>1</sup>, Lucia Ballerini<sup>1</sup> and Joanna M Wardlaw<sup>1,2</sup>

**Affiliations:**

<sup>1</sup> Division of Neuroimaging, Centre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, UK

<sup>2</sup> UK Dementia Institute at the University of Edinburgh, UK

**Corresponding Author:**

Joanna M Wardlaw, Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom. Email: joanna.wardlaw@ed.ac.uk

**Keywords:** Perivascular Spaces; Small Vessel Disease; risk factors; stroke; dementia; neuroimaging; systematic review;

**Word count:** abstract 177 words; manuscript 4912 words; references 44; supplement.

**Tables:** 2

**Figures:** Fig 1, 2, 3abc

## **Abstract**

**Background:** Perivascular Spaces (PVS), visible on brain magnetic resonance imaging (MRI), are thought to be associated with small vessel disease (SVD), neuroinflammation, and to be important for cerebral haemodynamics and interstitial fluid drainage.

**Aims:** To benchmark current knowledge on PVS associations with risk factors, neurological disorders, and neuroimaging lesions, using systematic review and meta-analysis.

**Summary of review:** We searched three databases for PVS publications, calculated odds ratios with 95% confidence interval and performed meta-analyses to assess adjusted associations with PVS. We identified 116 relevant studies (n=36,108) but only 23 (n=12,725) were meta-analysable. PVS assessment, imaging and clinical definitions varied. PVS were associated (n; OR, 95%CI, p) with ageing (8395; 1.47, 1.28-1.69, p=0.00001), hypertension (7872; 1.67, 1.20-2.31, p=0.002), lacunes (4894; 3.56, 1.39-9.14, p=0.008), microbleeds (5015; 2.26, 1.04-4.90, p=0.04) but not WMH (4974; 1.54, 0.71-3.32, p=0.27), stroke or cognitive impairment. There was between-study heterogeneity. Lack of appropriate data on other brain disorders and demographic features such as ethnicity precluded analysis.

**Conclusions:** Despite many studies, more are required to determine potential pathophysiological PVS involvement in cerebrovascular, neurodegenerative and neuroinflammatory disorders.

## Introduction

Perivascular spaces (PVS), also known as Virchow-Robin Spaces, are seen on magnetic resonance imaging (MRI) as thin linear or small punctate structures, of similar signal to CSF, in deep grey or white matter.<sup>1</sup> Increasing numbers of reports have detailed associations of visible PVS on MRI over the last two decades, notably with small vessel disease (SVD) lesions. PVS may provide an early biomarker for diagnosing developing disorders such as white matter hyperintensities (WMH)<sup>2</sup> which increase the risk of stroke and dementia,<sup>3</sup> or neurodegenerative diseases,<sup>4</sup> and are highly heritable.<sup>5</sup>

We aimed to benchmark current knowledge of associations between PVS and vascular risk factors, common neurological disorders and neuroimaging findings using systematic review with meta-analysis of all available published data.

## Methods

We registered the study protocol (PROSPERO, CRD42017056052) and used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Guidelines<sup>6</sup>.

### *Search Strategy*

We searched comprehensively for studies published in full up to January 14, 2017, in PubMed, Web of Science and Ovid EMBASE. The search keywords included “perivascular spaces”, “perivascular space”, “Virchow-robin spaces”, or “Virchow-robin space”, combined with “MRI”, “MR” or “magnetic resonance”. We assessed articles with any combination of the above keywords and checked reference lists of review papers, our files, and hand searched the last five years of *Stroke*.

### *Inclusion and Exclusion Criteria*

We aimed to include all papers that reported on PVS associations with vascular risk factors, common neurological disorders particularly cognitive impairment, dementia or stroke, or neuroimaging signs of vascular disease. We excluded case reports, animal studies and reviews without original data, studies with fewer than 10 subjects, on rare diseases, that were not published in English (we lacked resources for translation), lacked MRI, or did not provide quantitative data (or where quantitative data could not be extracted) on associations with PVS.

### *Data Extraction*

We removed duplicates, screened the remaining titles and abstracts, removed irrelevant papers and assessed the remaining potentially eligible papers for inclusion.

Two reviewers (FFF, LB) extracted title, authors, publication year, number of subjects, mean age, sex, PVS location (basal ganglia, centrum semiovale, midbrain or hippocampus), rating method and scale used, and results of associations, including whether adjusted for major covariates. We used results that had been adjusted for major covariates wherever they were available.

We extracted criteria on study quality, four on risk of bias (patient selection, index test, reference standard, study timing) and three on applicability (patient selection, index test, reference standard), from the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) criteria (<https://www.ncbi.nlm.nih.gov/pubmed/22007046>).

We excluded duplicate data, including only the most recent or largest dataset from studies with multiple publications, but included all available outcomes. Disagreement was resolved by consensus or by a third reviewer (JW) who also double-checked the data extraction (JW).

Where associations were not provided as odds ratios (ORs) and 95% Confidence Intervals (CI) we calculated the ORs and 95%CI if possible. Where relevant information appeared to be available but was not in the publication, we sought additional information from authors. Where studies met all inclusion criteria except for providing data for meta-analysable ORs, we performed a qualitative narrative summary of the findings.

### *Statistical Analysis*

We entered the ORs and 95% CI into Review Manager Software Version 5.3 (Cochrane, Oxford) for meta-analysis. We used generic inverse variance method and random effects model, plotted multivariate adjusted ORs and 95%CI and generated summary ORs. We assessed between-study heterogeneity using  $\chi^2$  test, with  $p < 0.05$  considered statistically significant, and used Higgin's  $I^2$  test to calculate the percentage of variance across studies due to heterogeneity rather than chance.<sup>7</sup>  $I^2$  of 25% or less was considered low, 26%-50% or

less moderate, 51-75% or less high and 76% and above as very high heterogeneity. We assessed publication bias using funnel plots.

## Results

We identified 956 non-duplicate papers, and eliminated 301 studies based on title and abstract. Of the remaining 654 studies screened in full, 116 studies met the inclusion criteria. However, of these 116 studies, only 23/116 provided their results as ORs and were therefore suitable for meta-analysis. Supplementary Figure 1 summarises the search and selection.

### *Characteristics of 23 studies included in meta-analysis*

The 23 studies with data suitable for meta-analysis included 12,725 patients (median N=268) from various demographic backgrounds (Table 1), performed in various geographical regions including the UK, Netherlands, Belgium, France, Sweden, China, Japan, USA and Canada.<sup>8-14</sup> The Northern Manhattan study included Hispanic, black, white and other populations,<sup>15</sup> but no studies presented data by ethnic group. The cohorts included men and women of age >50. They included individuals with previous history of stroke and patients from memory clinics. Several studies reported multiple association, e.g., ageing and hypertension vs. PVS.<sup>16</sup>

On QUADAS-2 criteria, no studies were judged to have a high risk of bias, only 3/23 studies had unclear risk, with the rest being low risk; 3/23 studies were judged to have high risk of applicability concerns and the rest low risk (Supplementary Table 1).

Most papers used 1.5T MRI, 11/23 used T2 and the rest a mix of T1 and T2 sequences to identify PVS. Most studies reported on PVS in the basal ganglia (BG) and centrum semiovale (CS) although several papers reported PVS in the hippocampus.<sup>12, 13</sup>

Several PVS rating scales were used, one of the commonest being the scale of Potter<sup>17</sup> which classifies PVS by count into four categories from 0 (no PVS) to 4 (>40 PVS). Other papers used a categorical scale of Heier<sup>18</sup> which classifies PVS by their diameters into three categories: grade 1 (<2mm), grade 2 (2-3 mm) and grade 3 (>3mm). Others include the scale of Patankar,<sup>19</sup> which rates PVS according to brain regions, and the scale of Adams<sup>20</sup> which rates PVS  $\geq 1$ mm separately from  $\geq 3$ mm. Several studies used their own PVS method.<sup>10, 21</sup>

The included studies distinguished PVS from lacunes, according to size, shape and location as described in the STRIVE standards.<sup>22</sup>

### *Characteristics of 93 studies that could not be meta-analysed*

The 93/116 non-meta-analysable studies (n=23,383) assessed 52 different risk factors, clinical or neuroimaging variables for their associations with PVS (Supplementary Table 2) as follows (numbers are number of studies):

Risk factors: ageing (4), hypertension (2), inflammation (2), hypercholesterolaemia (1) and 1 study each on adiponectin, blood brain barrier, peptide levels, PTEN mutation, and retinal microvascular calibre;

Clinical disorders: vascular disease unspecified (6), cognitive decline or Alzheimer's disease (6), unspecified dementia (4), stroke (4), large artery atheroma (2), Parkinsons disease (2), HIV (3), multiple sclerosis (4), depression (3), headache (3), head injury (2), myotonic dystrophy (2), systemic lupus erythematosus (SLE)/immunocompromised patients (2), autism (3), obsessive compulsive disorder (2), glaucoma (2), and 1 study each on tuberous sclerosis, unspecified neurological disorders, CADASIL, Tourette syndrome, adrenoleukodystrophy, asthma, hydrocephalus, infection, AGU, sickle cell anaemia, normal pressure hydrocephalus; Neuroimaging: WMH (8), cerebral amyloid angiopathy (CAA) (5), microbleeds (1), microinfarcts (1), lacunes (1), and atrophy (1).

### *Meta-Analysis*

The following meta-analyses of PVS associations are summarised in Table 2. There was no consistent evidence of publication bias in any of the following meta-analyses (see Supplement).

#### Risk factors

Ageing. Thirteen studies (n=8395) reported on ageing and PVS in BG, CS or Hippocampus (Table 2, Figure 1). PVS increased with age in all areas, most in the BG (OR 1.47, 95%CI 1.28, 1.69,  $P<0.00001$ ), then CS (OR=1.26, 95% CI, 1.07-1.49,  $P=0.005$ ), then hippocampus (OR=1.14, 95% CI, 1.01, 1.30,  $P=0.03$ ), difference between the three areas  $\chi^2 = 7.10$ ,  $P=0.03$  and between-study heterogeneity (BG,  $\chi^2=218.80$ ,  $p=0.00001$ ,  $I^2=96\%$ ; CS  $\chi^2= 42.82$ ,  $p=0.0001$ ,  $I^2=86\%$ ).




Figure 1 Forest plot of associations of PVS in BG, CS and Hippocampus with ageing

**Diabetes.** Five studies (n=3095) found no association between diabetes and PVS (Table 2, Supplementary figure 2).

**Hypertension.** Thirteen studies (n=7872) found BG PVS were associated with hypertension (OR=1.67, 95% CI, 1.20-2.31, P=0.002), with significant between-study heterogeneity ( $\chi^2=63.72$ , p=0.00001,  $I^2=84\%$ ), Figure 2. The direction of effect was similar for CS PVS but did not reach significance.






Figure 2 Forest plot of associations of PVS in BS and CS with hypertension

## Neurological Diseases

**Lacunar versus non-lacunar stroke.** Five studies ( $n=1,173$ ) showed no consistent association between BG or CS PVS in clinically-evident lacunar versus non-lacunar stroke subtypes,<sup>9, 13, 21, 23, 24</sup> (Table 2, Supplementary figure 3). However, stroke subtyping and imaging methods differed between studies.

**Acute stroke.** Two studies ( $n=682$ )<sup>25, 26</sup> found no association between acute stroke of any subtype and PVS, but only in CS (OR=3.99, 95% CI, 0.47-34.17,  $P=0.21$ ), (Table 2, Supplementary Figure 4).

**Cognitive impairment.** Three studies ( $n=1,272$ ) did not find an association between cognitive impairment and PVS in BG region (OR=1.21, 95% CI, 0.84-1.73,  $P=0.31$ ), Table 2, Supplementary Figure 5). Only 1 study<sup>27</sup> assessed cognition and CS PVS finding a borderline significant association (OR=1.06, 95% CI, 1.00-1.11). Amongst the 93 non-meta-analysable studies, only four assessed associations of PVS with dementia but all reported different statistics. Of these, three found that PVS were increased significantly in patients with dementia vs controls.<sup>19, 28, 29</sup> Three other studies examined associations of PVS and cognitive impairment, of which two found increased PVS with declining cognition.<sup>30, 31</sup>

### *Neuroimaging Features:*

*White matter hyperintensities.* Eight studies (n=4974) examined WMH and PVS in BG and CS regions (Figure 3a). Although the direction of effect was for an association with WMH, it did not reach significance (OR 1.54, 95%CI 0.71, 3.32, P=0.27). Amongst the 93 non-meta-analysable studies, eight (n=3,333, range 32-1818) reported on associations of PVS and WMH. These used different statistics (adjusted beta, r, rho, chi squared) precluding direct comparison. However, most found positive associations between BG PVS and WMH with adjusted betas of 0.19 (p<0.001)<sup>16</sup> to 0.47 (p<0.0001),<sup>2</sup> and only one found a negative association.<sup>32</sup>

*Lacunes.* Four studies (n=4894) found an association between lacunes and PVS in the BG (OR= 3.56, 95% CI, 1.39-9.14) but not CS region. There was high between-study heterogeneity (BG,  $\chi^2=27.72$ , p=0.00001,  $I^2=89\%$ ), Figure 3b.

*Microbleeds.* Five studies (n=5015) found that cerebral microbleeds were associated with BG PVS (OR=2.26, 95% CI, 1.25-4.00, P=0.04), but with between-study heterogeneity ( $\chi^2=27.35$ , p=0.00001,  $I^2=85\%$ ), Figure 3c. There were insufficient data to compare PVS and microbleeds by lobar or deep location.

*Cortical Superficial Sclerosis (cSS).* Two studies (n=1642) reporting on cSS and PVS found no association between combined BG and CS PVS and cSS (OR=2.28, 95% CI, 0.75-9.13, Supplementary Figure 6).




Figure 3 Forest plot of associations of PVS in BG and CS with WMH (a), lacunes (b), and cerebral microbleeds (c)

## Discussion

We investigated vascular risk factor, clinical, and imaging lesion associates of PVS by meta-analysing risk factor-adjusted odds ratios. Although we found 116 potentially relevant papers, only 23 studies provided meta-analysable data, representing nearly 13,000 participants from various demographic groups, world regions and ethnicities. Surprisingly, we did not find conclusive evidence that PVS were associated with some expected clinical or neuroimaging features, although we did find most expected risk factor associations. There was no consistent association of PVS with lacunar vs non-lacunar stroke and a surprising lack of meta-analysable data on PVS and cognitive decline or dementia. Most surprisingly, although the direction of effect was positive, the association between PVS and WMH was not significant in meta-analysis.

We used risk-factor adjusted ORs, suggesting that some previously described PVS-WMH associations may reflect shared co-associations or differences in population characteristics. However, most of the eight non-meta-analysable papers on WMH (Supplementary Table 2) did account for key co-variates and did show WMH to be associated with PVS. Thus, the overall direction of effect suggests that PVS are associated with WMH. For microbleeds, there were fewer studies but a larger sample size (Table 2) than WMH for meta-analysis, perhaps reflecting the more recent description of microbleeds with more consistent methods thus facilitating meta-analysis. Although we confirmed a PVS association with microbleeds, the high heterogeneity indicates that more data are required.

Data were very limited for testing associations of PVS with stroke, cognitive impairment, dementia or sleep disorders. This was disappointing, since brain fluid drainage via PVS is thought to be important for maintaining brain health, and indicates the need for more research.

We meta-analysed the BG and CS PVS separately, since regional PVS associations may differ, there are known vessel wall anatomical differences between the BG and CS, hence meta-analysing the regions separately was biologically plausible.<sup>19</sup> Some variation in PVS associations between BG and CS may reflect a lack of data for one region indicating that +future studies should assess both regions. Alternatively, PVS may vary between brain regions, although the association of PVS and ageing, for which we had the most data, did not differ by brain region (Figure 2).

Overall, the studies had low risk of bias or applicability concerns (Supplementary Table 1), but there was high between-study heterogeneity for many associations, indicating the need for more data. Inconsistencies between studies included use of different PVS and lesion rating methods, disease diagnosis, scanner strength and sequences, although lack of data precluded further sensitivity testing. Alternatively, PVS differences may reflect unquantified demographic, genetic or environmental differences. The epidemiological origin of the cohorts may also influence results, however it was not possible to test effects of country or ethnic origin since the data were not provided. Although we did not find objective evidence of publication bias, it is likely to be present.<sup>33</sup> We were not able to include non-English language publications, but found many papers and the meta-analysed studies included nearly 13,000 subjects.

Computational methods to assess PVS are now emerging,<sup>34-36</sup> show promise for future large studies, may help reduce variability, and can provide PVS volume, orientation, location in the brain in addition to count or frequency which may increase sensitivity for detecting subtle associations. Future research should maximise sample size, report imaging methods in detail, adjust analyses to account for important co-variables especially vascular risk factors and age, and assess a much wider range of subject groups to investigate more fully the characteristics of PVS in different clinical situations.

## **Conclusion**

Ageing, hypertension, cerebral microbleeds and lacunes were associated with PVS in risk-factor adjusted meta-analysis, with most data available for BG PVS. More studies are required to further validate the use of PVS as a risk marker for these diseases and to understand pathophysiological pathways for stroke, dementia and other common neurological disorders. Future studies should use consistent methods to determine PVS appearances, standard definitions and reporting of parameters for rating PVS.

## **Declaration of conflicting interests**

The research was conducted without any commercial or financial relationships that could be construed as a potential conflicts of interest.

## **Funding**

Engineering and Physical Sciences Research Council (EP/M005976/1); Row Fogo Centre for Research into Ageing and the Brain (Ref No: AD.ROW4.35. BRO-D.FID3668413); Age UK and UK Medical Research Council (G0701120, G1001245 and MR/M013111/1); Fondation Leducq (ref no. 16 CVD 05); the EU Horizon2020, PHC-03-15, project No 666881, ‘SVDs@Target’ and the MRC UK Dementia Research Institute.

## **Data Availability**

All data used in this manuscript are publicly available in the original publications; the extracted data are available from the authors on request.

## References

1. Kwee RM and Kwee TC. Virchow-Robin Spaces at MR Imaging. *RadioGraphics*. 2007; 27: 1071-86.
2. Aribisala BS, Wiseman S, Morris Z, et al. Circulating inflammatory markers are associated with magnetic resonance imaging-visible perivascular spaces but not directly with white matter hyperintensities. *Stroke*. 2014; 45: 605-7.
3. DeBette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2010; 341: c3666.
4. Ramirez J, Berezuk C, McNeely AA, Gao F, McLaurin J and Black SE. Imaging the Perivascular Space as a Potential Biomarker of Neurovascular and Neurodegenerative Diseases. *Cellular and Molecular Neurobiology*. 2016; 36: 289-99.
5. Duperron MG, Tzourio C, Sargurupremraj M, et al. Burden of Dilated Perivascular Spaces, an Emerging Marker of Cerebral Small Vessel Disease, Is Highly Heritable. *Stroke*. 2018; 49: 282-7.
6. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Chinese edition). 2009, p. 889-96.
7. Higgins JPT, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. *BMJ : British Medical Journal*. 2003; 327: 557-60.
8. Ohba H, Pearce L, Potter G and Benavente O. Enlarged perivascular spaces in lacunar stroke patients. THE secondary prevention of small subcortical stroked (SPS3) trial. *Stroke Conference*. 2012; 43.
9. Charidimou A, Meegahage R, Fox Z, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. *Journal of neurology, neurosurgery, and psychiatry*. 2013; 84: 624-9.
10. Klarenbeek P, Van Oostenbrugge RJ, Lodder J, Rouhl RPW, Knottnerus ILH and Staals J. Higher ambulatory blood pressure relates to enlarged Virchow-Robin spaces in first-ever lacunar stroke patients. *Journal of Neurology*. 2013; 260: 115-21.
11. Yakushiji Y, Charidimou A, Hara M, et al. Topography and associations of perivascular spaces in healthy adults; The kashima scan study. *Neurology*. 2014; 83: 2116-23.
12. Yao M, Hervé D, Jouvent E, et al. Dilated perivascular spaces in small-vessel disease: A study in CADASIL. *Cerebrovascular Diseases*. 2014; 37: 155-63.
13. Potter GM, Doubal FN, Jackson CA, et al. Enlarged perivascular spaces and cerebral small vessel disease. *International Journal of Stroke*. 2015; 10: 376-81.
14. Shams S, Martola J, Charidimou A, et al. Cortical superficial siderosis: Prevalence and biomarker profile in a memory clinic population. *Neurology*. 2016: 1-8.
15. Gutierrez J, Rundek T, Ekind MSV, Sacco RL and Wright CB. Perivascular Spaces Are Associated with Atherosclerosis: An Insight from the Northern Manhattan Study. *American Journal of Neuroradiology*. 2013; 34: 1711-6.
16. Rouhl RPW, van Oostenbrugge RJ, Knottnerus ILH, Staals JEA and Lodder J. Virchow-Robin spaces relate to cerebral small vessel disease severity. *Journal of neurology*. 2008; 255: 692-6.
17. Potter GM, Chappell FM, Morris Z and Wardlaw JM. Cerebral Perivascular Spaces Visible on Magnetic Resonance Imaging: Development of a Qualitative Rating Scale and its Observer Reliability. *Cerebrovascular Diseases (Basel, Switzerland)*. 2015; 39: 224-31.

18. Heier LA, Bauer CJ, Schwartz L, Zimmerman RD, Morgello S and Deck MDF. Large Virchow-Robin spaces: MR-clinical correlation. *American Journal of Neuroradiology*. 1989; 10: 929-36.
19. Patankar TF, Mitra D, Varma A, Snowden J, Neary D and Jackson A. Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: study in elderly patients with dementia. *AJNR American journal of neuroradiology*. 26: 1512-20.
20. Adams HHH, Cavalieri M, Verhaaren BFJ, et al. Rating method for dilated Virchow-Robin spaces on magnetic resonance imaging. *Stroke*. 2013; 44: 1732-5.
21. Zhang C, Chen Q, Wang Y, et al. Risk factors of dilated Virchow-Robin Spaces are different in various brain regions. *PLoS ONE*. 2014; 9.
22. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *The Lancet Neurology*. 2013; 12: 822-38.
23. Arba F, Quinn TJ, Hankey GJ, et al. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. *International journal of stroke : official journal of the International Stroke Society*. 2016: 1747493016666091-.
24. Doubal FN, MacLulich AMJ, Ferguson KJ, Dennis MS and Wardlaw JM. Enlarged Perivascular Spaces on MRI Are a Feature of Cerebral Small Vessel Disease. *Stroke*. 2010; 41.
25. Bae J-H, Park K-Y, Kim J-M and Park M-S. Abstract WP211: The Association Between Arterial Stiffness and Perivascular Space Topography in Stroke Patients. *Stroke*. 2016; 47: AWP211 LP-AWP.
26. Wu B, Yao X, Lei C, Liu M and Selim MH. Enlarged perivascular spaces and small diffusion-weighted lesions in intracerebral hemorrhage. *Neurology*. 2015; 85: 2045-52.
27. Uiterwijk R, Huijts M, Staals J, et al. Subjective cognitive failures in patients with hypertension are related to cognitive performance and cerebral microbleeds. *Hypertension*. 2014; 64: 653-7.
28. Zhu YC, Tzourio C, Soumaré A, Mazoyer B, Dufouil C and Chabriat H. Severity of dilated virchow-robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: A population-based study. *Stroke*. 2010; 41: 2483-90.
29. Beak HW, Choi HJ, Byun MS, et al. Prevalence of enlarged perivascular spaces in a memory clinic population. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2015; 11: P146.
30. Chen W, Song X and Zhang Y. Assessment of the Virchow-Robin Spaces in Alzheimer disease, mild cognitive impairment, and normal aging, using high-field MR imaging. *AJNR Am J Neuroradiol*. 2011; 32: 1490-5.
31. MacLulich AMJ, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR and Deary IJ. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. *J Neurol Neurosurg Psychiatry*. 2004; 75: 1519-23.
32. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. *Neurology*. 2014; 83: 794-800.
33. Yang H, Shen R, Jin Z, et al. Dilated Virchow–Robin Spaces in First-Ever Lacunar Stroke Patients: Topography and Clinical Correlations. *Journal of Stroke and Cerebrovascular Diseases*. 2016; 25: 306-11.
34. Ballerini L, Lovreglio R, Hernández MdCV, et al. Application of the Ordered Logit Model to Optimising Frangi Filter Parameters for Segmentation of Perivascular Spaces. *Procedia Computer Science*. 2016; 90: 61-7.



35. González-Castro V, Valdés Hernández MdC, Armitage PA and Wardlaw JM. Automatic Rating of Perivascular Spaces in Brain MRI Using Bag of Visual Words. Springer, Cham, 2016, p. 642-9.
36. Ballerini L, Lovreglio R, Hernandez MDV, et al. Perivascular Spaces Segmentation in Brain MRI Using Optimal 3D Filtering. *Sci Rep-Uk*. 2018; 8.
37. Charidimou A, Jager RH, Peeters A, et al. White matter perivascular spaces are related to cortical superficial siderosis in cerebral amyloid angiopathy. *Stroke*. 2014; 45: 2930-5.
38. Doubal FN, MacLulich AMJ, Ferguson KJ, Dennis MS and Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. *Stroke*. 2010; 41: 450-4.
39. Gutierrez J, Elkind MS, Cheung K, Rundek T, Sacco RL and Wright CB. Pulsatile and steady components of blood pressure and subclinical cerebrovascular disease: the Northern Manhattan Study. *J Hypertens*. 2015; 33: 2115-22.
40. Hurford R, Charidimou A, Fox Z, Cipolotti L, Jager R and Werring DJ. MRI-visible perivascular spaces: relationship to cognition and small vessel disease MRI markers in ischaemic stroke and TIA. *J Neurol Neurosurg Psychiatry*. 2014; 85: 522-5.
41. Klarenbeek P, van Oostenbrugge RJ, Rouhl RPW, Knottnerus ILH and Staals J. Ambulatory Blood Pressure in Patients With Lacunar Stroke. *Stroke*. 2013; 44: 2995 LP-9.
42. Loos CMJ, Klarenbeek P, van Oostenbrugge RJ and Staals J. Association between Perivascular Spaces and Progression of White Matter Hyperintensities in Lacunar Stroke Patients. *PLOS ONE*. 2015; 10: e0137323-e.
43. Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, et al. Topography of dilated perivascular spaces in subjects from a memory clinic cohort. *Neurology*. 2013; 80: 1551-6.
44. Riba-Llena I, Nafria C, Mundet X, et al. Assessment of enlarged perivascular spaces and their relation to target organ damage and mild cognitive impairment in patients with hypertension. *European journal of neurology*. 2016; 23: 1044-50.
45. Zhang X, Ding L, Yang L, et al. Brain atrophy correlates with severe enlarged perivascular spaces in basal ganglia among lacunar stroke patients. *PLoS ONE*. 2016; 11.

**Table 1:** Characteristics of studies included in the meta-analysis. WMH: white matter hyperintensities, MB: microbleeds, CMB: cerebral microbleeds, ICH: intracranial haemorrhage.

| No. | Reference                          | Number of Subjects | Age (mean) | Subject Characteristics                       | Disorder Associated  | Association test result, OR (95% CI) | Brain Region | Geographic Region | Rating Scale | Type of scanner MRI sequence |
|-----|------------------------------------|--------------------|------------|---|----------------------|--------------------------------------|--------------|-------------------|--------------|------------------------------|
| 1   | Arba et al 2016 <sup>23</sup>      | 430                | 64.7       | Ischemic stroke and transient icshemic attack | Lacunar stroke       | 0.91 (0.50-1.67)                     | BG           | Australia         | 5 point      | NA, T1, T2 and FLAIR         |
|     |                                    |                    |            |   | Lacunar stroke       | 1.18 (0.67-2.08)                     | CS           |                   |              |                              |
|     |                                    |                    |            |   | Hypertension         | 1.56 (0.08-3.04)                     | CS           |                   |              |                              |
|     |                                    |                    |            |   | Hypertension         | 2 (1.10-3.63)                        | BG           |                   |              |                              |
|     |                                    |                    |            | Ischemic Stroke and Transient Ischemic Attack | Cognitive impairment | 1.59 (1.07-2.39)                     | CS           | UK                |              |                              |
|     |                                    |                    |            |   | WMH                  | 2.24 (1.29-3.89)                     | BG           |                   |              |                              |
|     |                                    |                    |            |   | WMH                  | 1.39 (0.80-2.42)                     | CS           |                   |              |                              |
| 2   | Bae et al 2016 <sup>25</sup>       | 481                | 68.2       | Acute Stroke                                  | Arterial stiffness   | 1.7 (1.0-2.7)                        | BG           | China             | 4 points     | NA T2                        |
| 3   | Charidimou et al 2013 <sup>9</sup> | 121                | NA         | ICH   | Deep MB              | 3.27 (1.27-8.45)                     | BG           | UK& Belgium       | 4 points     | 1.5T, T1, T2, FLAIR          |
|     |                                    |                    |            |   | Lacunar Infarcts     | 1 (1-1.01)                           | BG           |                   |              |                              |
|     |                                    |                    |            |   | Lobar MB             | 0.43 (0.16-1.20)                     | BG           |                   |              |                              |

|   |                                     |     |      |   |                                |                   |    |                |          |                |
|---|-------------------------------------|-----|------|---|--------------------------------|-------------------|----|----------------|----------|----------------|
|   |                                     |     |      |   | Deep MB                        | 0.91 (0.35-2.38)  |    |                |          |                |
|   |                                     |     |      |   |                                | 1 (0.99-1)        | CS |                |          |                |
|   |                                     |     |      |   | Lacunar Infarcts               | 1.92 (0.74-4.96)  | CS |                |          |                |
|   |                                     |     |      |   | Lobar MB                       | 1.43 (1.01-2.02)  | CS |                |          |                |
|   |                                     |     |      |   |                                | 1.5 (1.08-2.10)   |    |                |          |                |
|   |                                     |     |      |   | Ageing                         |                   | BG |                |          |                |
|   |                                     |     |      |   | Ageing                         |                   | CS |                |          |                |
| 4 | Charidimou et al 2014 <sup>37</sup> | 138 | 71.8 | Cerebral amyloid angiopathy               | Cortical Superficial Siderosis | 4.78 (1.64–13.87) | CS | UK and Belgium | 4 points | 1.5T, T2&FLAIR |
|   |                                     |     |      |   | Ageing                         | 1.02 (0.97–1.06)  | CS |                |          |                |
|   |                                     |     |      |   | Hypertension                   | 0.27 (0.10–0.74)  | CS |                |          |                |
| 5 | Doubal et al 2010 <sup>38</sup>     | 235 | NA   | Acute ischemic lacunar or cortical stroke | Lacunar stroke                 | 3.16 (1.49–6.70)  | BG | UK             | 4 points | NA T2          |
|   |                                     |     |      |   | Ageing                         | 1.03 (0.99–1.08)  | BG |                |          |                |
|   |                                     |     |      |   | Diabetes                       | 0.65 (0.24–1.74)  | BG |                |          |                |
|   |                                     |     |      |   |                                | 2.03 (1.10–3.74)  | BG |                |          |                |
|   |                                     |     |      |   | WMH                            | 1.33 (0.63–2.81)  | BG |                |          |                |
|   |                                     |     |      |   | Hypertension                   |                   | BG |                |          |                |

|   |                                     |      |      |                           |              |                   |         |             |                                      |                 |
|---|-------------------------------------|------|------|---------------------------|--------------|-------------------|---------|-------------|--------------------------------------|-----------------|
| 6 | Gutierrez et al 2015 <sup>39</sup>  | 1290 | 64   | Stroke-free               | Hypertension | 1.14 (1.03-1.26)  | Overall | US          | NA                                   | 1.5T, T1& FLAIR |
| 7 | Hurford et al 2014 <sup>40</sup>    | 246  | 62   | Stroke                    | Lacunes      | 2.93 (1.10-7.84)  | BG      | UK          | 4 points                             | NA T2           |
|   |                                     |      |      |                           | Lobar CMB    | 0.82 (0.42-1.60)  | BG      |             |                                      |                 |
|   |                                     |      |      |                           | Deep CMB     | 1.77 (0.59-5.33)  | BG      |             |                                      |                 |
|   |                                     |      |      |                           | Lacunes      | 1.58 (0.45-5.57)  | CS      |             |                                      |                 |
|   |                                     |      |      |                           | Lobar CMB    | 1.34 (0.60-2.95)  | CS      |             |                                      |                 |
|   |                                     |      |      |                           | Ageing       | 1.18 (0.98-1.43)  | BG      |             |                                      |                 |
|   |                                     |      |      |                           | Ageing       | 1.19 (1.04-1.37)  | CS      |             |                                      |                 |
|   |                                     |      |      |                           | WMH          | 1.27 (1.14-1.43)  | BG      |             |                                      |                 |
|   |                                     |      |      |                           | WMH          | 0.99 (0.89-1.10)  | CS      |             |                                      |                 |
|   |                                     |      |      |                           | Hypertension | 4.89 (1.39-17.21) | BG      |             |                                      |                 |
|   |                                     |      |      |                           | Hypertension | 3.71 (1.42-9.59)  | CS      |             |                                      |                 |
| 8 | Klarenbeek et al 2013 <sup>41</sup> | 122  | 64.6 | First ever lacunar stroke | Hypertension | 1.32 (1.05–1.65)  | BG      | Netherlands | 3 points                             | 1.5T or 3T T2   |
| 9 | Loos et al 2015 <sup>42</sup>       | 118  | 63   | First ever lacunar stroke | WMH          | 4.29 (1.28–14.32) | BG      | Netherlands | None, mild to moderate and extensive | 1.5T T2         |

|    |   |      |      |  |  |   |  |        |          |                        |
|----|---|------|------|--|--|---|--|--------|----------|------------------------|
| 10 | Martinez-Ramirez et al 2013 <sup>43</sup> | 89   | 72.7 | Massachusetts Alzheimer's Disease Research Centre          | Higher lobar MB<br>Strictly lobar MB<br>Hypertension   | 1.53 (1.06–2.21)<br>1.78 (0.97–3.27)<br>9.38 (1.03–85.17)   | WM<br>WM<br>BG   | US     | 4 points | 3T, T1 and T2          |
| 11 | Ohba et al 2012 <sup>8</sup>              | 1632 | NA   | The secondary Prevention of Small Subcortical Stroke trial | Multiple infarcts<br>Ageing<br>Hypertension  | 1.7 (1.2–2.3)<br>1.9 (1.7–2.1)<br>2.4 (1.7–3.4)   | BG<br>BG<br>BG   | Canada | 3 points | NA, T2                 |
| 12 | Potter et al 2015 <sup>13</sup>           | 298  | 68   | Stroke   | Lacunar stroke<br>Old infarcts<br>Lacunar stroke<br>Old Infarcts<br>Ageing<br>Ageing<br>Diabetes<br>Diabetes<br>WMH<br>WMH<br>Hypertension<br>Hypertension | 2.08 (1.04–4.17)<br>0.76 (0.40–1.45)<br>0.69 (0.37–1.29)<br>1.22 (0.66–2.23)<br>1.06 (1.02–1.09)<br>1.0 (0.98–1.03)<br>1.58 (0.56–4.46)<br>0.68 (0.24–1.98)<br>1.43 (0.81–2.54)<br>0.75 (0.44–1.29)<br>0.94 (0.50–1.76)<br>1.13 (0.63–2.01) | BG<br>BG<br>CS<br>CS<br>BG<br>CS<br>CS<br>BG<br>BG<br>CS<br>BG<br>CS | UK     | 4 points | 1.5T, T1, T2 and FLAIR |

|    |                                     |      |               |   |                                |                    |    |             |          |                    |
|----|-------------------------------------|------|---------------|---|--------------------------------|--------------------|----|-------------|----------|--------------------|
| 13 | Riba-Llena et al 2016 <sup>44</sup> | 733  | 62.8          | Hypertensive  | Mild cognitive impairment      | 1.59 (0.84-3.01)   | BG | Spain       | 4 points | 1.5T, T1&T2        |
|    |                                     |      |               |   | Ageing                         | 1.68 (1.37-2.06)   | BG |             |          |                    |
|    |                                     |      |               |   | Ageing                         | 1.38 (1.18-1.63)   | CS |             |          |                    |
|    |                                     |      |               |   | Diabetes                       | 0.94 (0.75-1.17)   | BG |             |          |                    |
|    |                                     |      |               |   | Diabetes                       | 0.93 (0.78-1.13)   | CS |             |          |                    |
|    |                                     |      |               |   | Hypertension                   | 0.92 (0.64-1.34)   | BG |             |          |                    |
|    |                                     |      |               |   | Hypertension                   | 1.24 (0.90-1.71)   | CS |             |          |                    |
| 14 | Rouhl et al 2008 <sup>16</sup>      | 165  | NA            | Patients with first lacunar stroke                        | Silet ischemic lesion          | 10.58 (3.40–32.92) | BG | Netherlands | 3 points | 1.5T T2            |
| 15 | Shams et al 2016 <sup>14</sup>      | 1504 | 63            | Dementia patients with small vessel disease and cognition | Cortical Superficial Siderosis | 1.73 (1.16-2.61)   | BG | Sweden      | 4 points | 1.5T, T1, T2&FLAIR |
|    |                                     |      |               |   |                                | 1.16 (0.70-1.92)   | CS |             |          |                    |
| 16 | Uiterwijk et al 2014 <sup>27</sup>  | 109  | 6.1           | Hypertensive  | Overall Cognition              | 0.99 (0.91–1.07)   | BG | Netherlands | 3 points | 1.5T, T2 and FLAIR |
|    |                                     |      |               |   |                                | 1.06 (1.00–1.11)   | CS |             |          |                    |
| 17 | Wu et al 2015 <sup>26</sup>         | 201  | Median: 70.97 | ICH   | spontaneous supratentorial ICH | 12.56 (4.40-35.85) | CS | Israel      | 4 points | 1.5T T2            |
|    |                                     |      |               |   |                                | 2.77 (0.93-8.24)   | BG |             |          |                    |
|    |                                     |      |               |   | Acute brain infarct            | 12.56 (4.4-35.85)  | CS | China       |          |                    |

|    |                                    |      |       |  |   |   |  |                    |           |                           |
|----|------------------------------------|------|-------|--|---|---|--|--------------------|-----------|---------------------------|
| 18 | Yakushiji et al 2014 <sup>11</sup> | 1740 | 57.1  | The Kashima Scan Study-age related brain changes | Deep of infratentorial CMB<br>Lobar CMB<br><br>Lacunes<br><br>Ageing<br><br>Diabetes<br><br>WMH<br><br>Hypertension | 2.77 (1.62-4.74)<br>1.54 (0.73-3.28)<br><br>3.35 (1.92-5.86)<br><br>1.11 (0.90-1.37)<br><br>0.8 (0.48-1.33)<br><br>2.17 (1.42-3.31)<br><br>2.03 (1.46-2.82) | BG<br>BG<br><br>BG<br><br>BG<br><br>BG<br><br>BG | Japan              | 4 points  | 1.5T<br>T2                |
| 19 | Yang et al 2016 <sup>33</sup>      | 16   | NA    | Stroke   | Lacunar infarct   | 1.204 (0.872-1.662)   | BG   | China              | 3 points  | 1.5,<br>T1 and 3T, T2     |
| 20 | Yao et al 2014 <sup>12</sup>       | 344  | 50.8  | Mutation in the Notch3 gene                      | Ageing<br>Ageing  | 2.23 (1.67-2.98)<br>1.6 (1.2-2.14)  | BG<br>CS   | France and Germany | 4 points  | 1.5T,<br>T1, T2 and FLAIR |
| 21 | Zhang et al 2014 <sup>21</sup>     | 1090 | NA    | Ischemic stroke or transition ischemic attack    | Lacunes<br>Ageing<br><br>Hypertension<br><br>Hypertension   | 1.36 (1.05-1.78)<br>2.79 (2.13-3.67)<br><br>1.13 (0.86-1.47)<br><br>2.01 (1.54-2.63)  | BG<br>BG<br><br>BG<br><br>CS                     | China              | Their own | 3.0T,<br>T2,<br>FLAIR&DWI |
| 22 | Zhang et al 2016 <sup>45</sup>     | 89   | 72.93 | Lacunar stroke                                   | Deep WMH<br>Brain Atrophy<br>Diabetes<br>WMH<br>Hypertension  | 0.78 (0.4-1.50)<br>1.40 (1.13-1.73)<br>0.94 (0.45-1.97)<br>1.88 (1.24-2.83)<br>1.67 (0.83-3.38)   | BG<br>BG<br>BG<br>BG<br>BG                       | China              | 4 points  | 3T,<br>T1, T2 and FLAIR   |

|    |                              |      |    |                       |                |                 |    |        |          |                 |
|----|------------------------------|------|----|-----------------------|----------------|-----------------|----|--------|----------|-----------------|
|    |                              |      |    |                       | Hypertension   |                 |    |        |          |                 |
| 23 | Zhu et al 2010 <sup>28</sup> | 1818 | NA | The Three-City cohort | Lacunar Stroke | 16.6 (6.0–45.9) | BG | France | 4 points | 1.5T, T1 and T2 |
|    |                              |      |    |                       | Ageing         | 2.1 (1.4-3.2)   | BG |        |          |                 |
|    |                              |      |    |                       | Ageing         | 1.5 (1.2-1.9)   | CS |        |          |                 |
|    |                              |      |    |                       | WMH            | 3.2 (2.5–4.1)   | BG |        |          |                 |
|    |                              |      |    |                       | WMH            | 1.2 (1.0–1.4)   | CS |        |          |                 |



**Table 2.** Summary of Odds Ratios and 95%CI for PVS associations from meta-analysis.

| Association of interest        | Location of PVS | Number of studies | N of subjects <sup>1</sup> | OR   | 95% CI     | P       | I <sup>2</sup> |
|--------------------------------|-----------------|-------------------|----------------------------|------|------------|---------|----------------|
| <i>Risk factors</i>            |                 |                   |                            |      |            |         |                |
| Age                            | BG              | 10                | 8395                       | 1.47 | 1.28-1.69  | 0.00001 | 96%            |
|                                | CS              | 7                 |                            | 1.26 | 1.07-1.49  | 0.005   | 86%            |
|                                | hippocampus     | 2                 |                            | 1.14 | 1.01-1.30  | 0.03    | 0%             |
| Hypertension                   | BG              | 11                | 7872                       | 1.67 | 1.20-2.31  | 0.002   | 84%            |
|                                | CS              | 6                 |                            | 1.42 | 0.92-2.20  | 0.12    | 77%            |
| Diabetes                       | BG              | 5                 | 3095                       | 0.9  | 0.74-1.08  | 0.26    | 0%             |
|                                | CS              | 2                 |                            | 0.95 | 0.78-1.15  | 0.58    | 0%             |
| <i>Neurological disorder</i>   |                 |                   |                            |      |            |         |                |
| Acute Stroke                   | CS              | 2                 | 682                        | 3.99 | 0.47-34.17 | 0.21    | 93%            |
| Lacunar v non-lacunar stroke   | BG              | 5                 | 1173                       | 1.26 | 0.83-1.93  | 0.28    | 69%            |
|                                | CS              | 2                 |                            | 0.92 | 0.54-1.55  | 0.75    | 36%            |
| Cognitive impairment           | BG              | 3                 | 1272                       | 1.21 | 0.84-1.73  | 0.31    | 51%            |
| <i>Neuroimaging feature</i>    |                 |                   |                            |      |            |         |                |
| White matter hyperintensities  | BG              | 8                 | 4974                       | 1.54 | 0.71-3.32  | 0.27    | 0%             |
|                                | CS              | 4                 |                            | 1.07 | 0.90-1.27  | 0.21    | 0%             |
| lacunes                        | BG              | 4                 | 4894                       | 3.56 | 1.39-9.14  | 0.008   | 89%            |
|                                | CS              | 2                 |                            | 0.87 | 0.67-1.13  | 0.31    | 0%             |
| microbleeds                    | BG              | 5                 | 5015                       | 2.26 | 1.04-4.90  | 0.04    | 85%            |
|                                | CS              | 2                 |                            | 1.15 | 0.62-2.12  | 0.66    | 0%             |
| Cortical superficial siderosis | BG/CS combined  | 2                 | 1642                       | 2.28 | 0.57-9.13  | 0.24    | 75%            |

<sup>1</sup> Indicates total sample for the association of interest.